| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.85M | 12.13M | ― | 6.10M | 5.23M |
| Gross Profit | 4.08M | 9.32M | -20.63M | 4.38M | -3.28M |
| EBITDA | -66.61M | -38.86M | -33.28M | -43.26M | -12.04M |
| Net Income | -74.82M | -46.25M | -38.08M | -51.86M | -18.08M |
Balance Sheet | |||||
| Total Assets | 226.10M | 263.34M | 189.59M | 302.98M | 202.86M |
| Cash, Cash Equivalents and Short-Term Investments | 42.56M | 78.63M | 73.93M | 142.74M | 136.66M |
| Total Debt | 70.42M | 68.22M | 31.34M | 41.41M | 20.01M |
| Total Liabilities | 88.51M | 83.74M | 38.20M | 51.85M | 24.68M |
| Stockholders Equity | 137.59M | 183.94M | 151.39M | 251.13M | 178.18M |
Cash Flow | |||||
| Free Cash Flow | -70.32M | -55.42M | -29.65M | -113.02M | -25.66M |
| Operating Cash Flow | -40.42M | -36.23M | -12.89M | -29.23M | -6.09M |
| Investing Cash Flow | -18.17M | -12.04M | -16.10M | -106.80M | -19.68M |
| Financing Cash Flow | 25.21M | 44.16M | ― | 180.69M | 103.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
48 Neutral | $1.63B | ― | -68.95% | ― | 45.98% | 44.14% | |
46 Neutral | $2.76B | ― | -95.42% | ― | 2.53% | -2.83% | |
42 Neutral | $50.42M | ― | -265.36% | ― | -3.53% | 24.37% | |
41 Neutral | $194.42M | ― | -29.51% | ― | 78.82% | -20.81% | |
38 Underperform | $274.35M | -2.47 | -45.13% | ― | -14.27% | -28.56% | |
26 Underperform | $33.68M | -0.89 | ― | ― | ― | 61.78% |
On November 19, 2025, NOVONIX Ltd announced the issuance of 7,534 ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of the conversion of performance rights. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its capital structure and incentivize its workforce. The newly issued securities will rank equally with existing shares, reinforcing NOVONIX’s commitment to aligning employee interests with those of its shareholders.
On November 4, 2025, NOVONIX Limited announced the termination of its offtake agreement with FCA US LLC, a subsidiary of Stellantis NV, due to disagreements over battery cell product specifications and production milestones. Despite this setback, NOVONIX remains committed to its partnerships with Panasonic and PowerCo and continues to provide samples to other potential customers. The company’s Riverside facility is set to become a major production site for synthetic graphite, with plans for a second plant to meet growing demand, aiming for a total production capacity of over 50,000 tonnes per year.
On November 4, 2025, NOVONIX Ltd announced the issuance of 5,482 ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of the conversion of performance rights. This move is part of the company’s employee incentive scheme, reflecting its commitment to rewarding performance and potentially strengthening its market position by aligning employee interests with shareholder value.
NOVONIX Ltd, a company involved in the energy sector, announced a change in substantial holding as of October 31, 2025. YA II PN, Ltd., a substantial holder, reduced its voting power from 7.91% to 6.80% by disposing of 9,288,631 fully paid ordinary shares. This change in shareholding could impact the company’s market dynamics and influence shareholder decisions.
On October 28, 2025, NOVONIX Limited announced the drawdown of an additional tranche of US$40 million in convertible debentures, netting US$38 million after a 5% discount. This funding, part of a previously established agreement with Yorkville Advisors Global, LP, was approved by shareholders in September 2025. The move is expected to bolster NOVONIX’s financial resources, enhancing its operations and market positioning in the battery technology industry.
On October 27, 2025, NOVONIX Limited, a company involved in the energy sector, announced a change in substantial holding. YA II PN, Ltd. reduced its voting power in NOVONIX from 9.213% to 7.91% through the disposal of shares on October 21 and 22, 2025. This change in holdings reflects a shift in investor interest and could impact the company’s market dynamics and stakeholder relationships.
On October 23, 2025, NOVONIX Ltd announced the issuance of 247,278 performance rights under its employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize its workforce, potentially impacting its operational efficiency and market positioning by aligning employee interests with corporate goals.
On October 16, 2025, NOVONIX Ltd announced a change in substantial holding, with YA II PN, Ltd. adjusting its voting power in the company. The changes, which occurred on October 14 and 15, 2025, involved the disposal and conversion of shares, resulting in an increase in voting power from 11.03% to 11.23%. This adjustment reflects strategic financial maneuvers that could impact NOVONIX’s market positioning and stakeholder interests.
NOVONIX Ltd, a company involved in the energy sector, recently announced a change in substantial holding. YA II PN, Ltd. reduced its voting power in NOVONIX from 11.23% to 9.21% through the disposal of shares on October 16 and 17, 2025. This change may impact the company’s shareholder dynamics and influence its market positioning.
On October 15, 2025, NOVONIX Limited, a company focused on the development and supply of advanced battery materials, announced a significant operational milestone. YA II PN, Ltd. became a substantial holder in NOVONIX, acquiring an 11.03% voting power with 87,358,939 fully paid ordinary shares as of October 13, 2025. This development could potentially strengthen NOVONIX’s market position by enhancing its shareholder base and possibly influencing future strategic decisions.
On October 15, 2025, NOVONIX Limited announced the issuance of 48,044,482 ordinary fully paid shares on the Australian Securities Exchange (ASX) following the conversion of convertible debentures. This move is part of the company’s strategy to strengthen its capital structure and enhance its market position in the battery materials industry. The newly issued shares are expected to rank equally with existing shares, potentially increasing liquidity and investor interest.
On October 13, 2025, NOVONIX Limited announced the issuance of 68,059,769 new ordinary shares on the Australian Securities Exchange (ASX) following the conversion of convertible debentures. This move is part of the company’s strategy to strengthen its capital base and enhance its market position in the competitive battery materials industry. The newly issued shares are expected to rank equally with existing shares, reflecting NOVONIX’s commitment to maintaining shareholder value and supporting its growth initiatives.
On October 10, 2025, NOVONIX Limited announced the issuance of 2,478 ordinary fully paid securities as a result of options being exercised or convertible securities being converted. These securities were issued under an employee incentive scheme and will be quoted on the ASX. This move reflects NOVONIX’s ongoing efforts to incentivize its workforce and align employee interests with company growth, potentially enhancing its industry positioning and stakeholder value.
On October 9, 2025, NOVONIX Limited announced the quotation of 29,213,548 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities were issued as a result of the conversion of convertible debentures. This move is part of NOVONIX’s strategy to strengthen its capital base and enhance its market presence, potentially impacting its operational capacity and stakeholder value positively.
On October 8, 2025, NOVONIX Ltd announced the issuance of 9,114,822 ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of converting convertible debentures. This move is part of the company’s strategy to strengthen its capital structure and enhance its market position in the energy storage industry. The newly quoted securities are expected to rank equally with existing securities, potentially increasing investor confidence and stakeholder interest in NOVONIX’s growth trajectory.
On October 7, 2025, NOVONIX Limited announced the issuance of 9,105,213 ordinary fully paid securities on the Australian Securities Exchange (ASX). This issuance results from the conversion of convertible debentures, reflecting the company’s strategic move to strengthen its capital structure. The newly issued securities will rank equally with existing shares, potentially impacting the company’s market positioning by increasing its equity base and providing additional resources for future growth initiatives.
On October 1, 2025, NOVONIX Limited announced the quotation of 14,749 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities were issued as a result of the conversion of performance rights under an employee incentive scheme. This move is part of NOVONIX’s strategy to enhance its capital structure and support its growth in the battery technology sector, potentially strengthening its market position and providing value to stakeholders.
On September 30, 2025, NOVONIX Ltd announced the issuance of 7,310,610 ordinary fully paid securities on the ASX as a result of converting convertible debentures. This move is part of the company’s strategy to strengthen its capital structure and potentially improve its market position in the battery technology industry. The securities are intended to be quoted on the ASX, reflecting NOVONIX’s ongoing efforts to expand its financial and operational capabilities.
On September 1, 2025, NOVONIX Limited announced the issuance of 250,000 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of the conversion of performance rights. This move is part of the company’s strategy to enhance its capital structure and support its ongoing growth in the battery materials sector. The new securities are intended to rank equally with existing shares, reflecting NOVONIX’s commitment to expanding its market presence and providing value to its stakeholders.
On September 1, 2025, NOVONIX Limited announced the cessation of 3,236,775 performance rights due to the lapse of conditional rights that were not met. This development affects the company’s issued capital and reflects a strategic adjustment in its equity securities management, potentially impacting investor perceptions and market positioning.